Barr’s Generic Premarin ANDA To Be Filed By June; Cenestin Sales Growing
Executive Summary
Barr Laboratories plans to submit an ANDA for generic Premarin (conjugated estrogens) by June without waiting for a decision in Wyeth's suit against Barr's ingredient supplier
You may also be interested in...
Barr Seasonale Print DTC Begins In March; TV Ads Debuting In Second Half
Barr will begin promoting its extended-regimen oral contraceptive Seasonale direct to consumers in March with print ads
Barr Seasonale Print DTC Begins In March; TV Ads Debuting In Second Half
Barr will begin promoting its extended-regimen oral contraceptive Seasonale direct to consumers in March with print ads
Barr Barred From Premarin Equine-Based Generics; ANDA Status Under Review
Barr Labs will meet with FDA to discuss the status of its conjugated estrogens ANDA following a district court decision barring the company from using Natural Biologics' raw material for an "AB"-rated generic